TY  - GEN
AU  - Robak,Tadeusz
AU  - Huang,Huiqiang
AU  - Jin,Jie
AU  - Zhu,Jun
AU  - Liu,Ting
AU  - Samoilova,Olga
AU  - Pylypenko,Halyna
AU  - Verhoef,Gregor
AU  - Siritanaratkul,Noppadol
AU  - Osmanov,Evgenii
AU  - Pereira,Juliana
AU  - Mayer,Jiri
AU  - Hong,Xiaonan
AU  - Okamoto,Rumiko
AU  - Pei,Lixia
AU  - Rooney,Brendan
AU  - van de Velde,Helgi
AU  - Cavalli,Franco
TI  - Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study
SN  - 1029-2403
PY  - 2019///1231
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Bortezomib
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Lymphoma, Mantle-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Progression-Free Survival
KW  - Survival Analysis
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1080/10428194.2017.1321750
ER  -